The results of a 3-year trial recently published in The Lancet provide compelling evidence that selective laser trabeculoplasty performed as a first-line treatment in newly diagnosed cases of glaucoma and ocular hypertension provides better control of IOP at a lower cost and with fewer side effects compared with medications. These findings caused a stir among glaucoma specialists and the ophthalmology community at large and may bring about a paradigm shift in the approach to glaucoma treatment.
“My personal view is that this study will transform policies and transform the initial
Uncategorized